Dose selection nyu 012815 2
-
Upload
jssilverman00 -
Category
Documents
-
view
107 -
download
0
Transcript of Dose selection nyu 012815 2
![Page 1: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/1.jpg)
Principles of Radiation Therapy
Joshua Silverman, MD, PhDDepartment of Radiation OncologyNYU Langone Medical CenterAugust 3, 2015
![Page 2: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/2.jpg)
The therapeutic ratio
![Page 3: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/3.jpg)
Dose selection for a future neurosurgeon
![Page 4: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/4.jpg)
Dose selection after a good plan is very satisfying
![Page 5: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/5.jpg)
![Page 6: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/6.jpg)
![Page 7: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/7.jpg)
Concept of dose• Since the invention of x-rays, radiation treatment needed to be
quantified, in a way that was comparable with it’s biological effect
• 1920-40’s The Erythema dose• Roentgen (R) The amount of radiation to create 1 esu in 1 cc• 1953: The Rad: 100 erg per gram• 1970’s: Gray (Gy) - The radiation to deposit 1 Joule in 1 kg of
tissue• Ultimate goal is to translate these “physics” definitions to
biologic effect in target and non-target tissues
![Page 8: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/8.jpg)
The five ‘R’s of Radiobiology• Repair• Repopulation• Redistribution• Radiosensitivity• Reoxygenation
These all modify the clinical effect of the radiation
![Page 9: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/9.jpg)
Brain metastases• How do we select dose?• Size – paradox with big tumor receiving smaller
dose?• Histology – for melanoma, we deliver a bit more• Location, location, location
![Page 10: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/10.jpg)
Brain metastases dose selection:
Margin doses:Small tumors, no prior RT = 20-22 GyLarger: 16-18 Gy-Lower doses feasible in breast cancer.-Melanoma, renal cell, sarcoma – use 18-20Gy
-Isodose: 50% margin allows high central dose-For small tumors, 60-80% isodose line at margin works well and can be efficient.
![Page 11: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/11.jpg)
![Page 12: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/12.jpg)
![Page 13: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/13.jpg)
RTOG Toxicity data: 90-05
![Page 14: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/14.jpg)
![Page 15: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/15.jpg)
Brain metastases• How do we select dose?• Size – paradox with big tumor receiving smaller dose?• Histology – for melanoma, we deliver a bit more• Location, location, location
• Often times, we select dose based on normal tissue tolerances
![Page 16: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/16.jpg)
Cranial neuropathy• We assume that cranial nerves are a quintessential
serial organ in terms of toxicity• Parallel organs, such as lung and kidney, often
have toxicities expressed as dose-volume relations without threshold effects
• Serial organs, such as the spinal cord, have maximum tolerated doses with threshold
![Page 17: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/17.jpg)
Board examination - ABR• “Dr. Silverman, what is your dose tolerance for the
optic nerve and/or the optic chiasm using SRS?”– “8 Gy”
• “Dr. Silverman, what is your dose tolerance to the brainstem using SRS?”– “12 Gy”
![Page 18: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/18.jpg)
![Page 19: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/19.jpg)
Optic Neuropathy: Mayo Clinic
Dose <8 Gy 8-10 Gy 10-12 Gy >12 Gy
Optic neuropathy
1/58 2/58 0/67 2/29
Pollock et al: IJROBP 55: 1177-81, 2003.4/215 pts with optic neuropathy (median dose = 10 Gy)
1 case: after 12.8 Gy with no prior XRT (risk 1/28?)3 cases: prior XRT: 58.8+7 Gy, 45+9 Gy, 50.4+9+12 GyBetter delineation of optic nerves/chiasm dose (MR vs CT)
![Page 20: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/20.jpg)
Optic Neuropathy: Graz
Dose <10 Gy 10-15 Gy >15 Gy
Optic neuropathy
0 % 27 % 78 %
Leber et al: J Neurosurg 88: 43-50, 1998.SRS for 50 pts with benign skull base tumors & FU 24-60 MO
No cavernous sinus neuropathy with doses of 5-20 Gy
![Page 21: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/21.jpg)
![Page 22: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/22.jpg)
Cranial neuropathy• Not quite as much data as we sometimes think• Often learn about dose tolerance by accident
– Initial dose used was too high and late side-effects observed– From varying context (e.g. temporal lobe necrosis in patients
treated for head and neck cancer)• We say 8 Gy, but few toxicities actually observed below
10 Gy and point doses up to 12 Gy may even be tolerated• What is our threshold/tolerance for tolerance?
![Page 23: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/23.jpg)
AVM control rates
![Page 24: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/24.jpg)
AVM control rates
![Page 25: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/25.jpg)
![Page 26: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/26.jpg)
![Page 27: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/27.jpg)
![Page 28: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/28.jpg)
![Page 29: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/29.jpg)
![Page 30: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/30.jpg)
![Page 31: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/31.jpg)
![Page 32: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/32.jpg)
![Page 33: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/33.jpg)
![Page 34: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/34.jpg)
![Page 35: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/35.jpg)
![Page 36: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/36.jpg)
![Page 37: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/37.jpg)
DEVELOPMENT OF A MODEL TO PREDICT PERMANENT SYMPTOMATIC POST-RADIOSURGERY INJURY FOR ARTERIOVENOUS MALFORMATION PATIENTS
.
![Page 38: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/38.jpg)
Necrosis after AVM Radiosurgery• Gamma knife: 425 patients • Marginal doses (Dmin)
– Range: 10-35 Gy, median = 20 Gy• Maximum dose (Dmax)
– Range: 20-60 Gy, median = 36 Gy• Median isodose = 50% (23-90%), MMDR: 1.11-4.43
• Treatment volume– Range: 0.26-143 cc, median = 7.3 cc
• Isocenters: median=2 (range: 1-21)
![Page 39: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/39.jpg)
Limitations of the PIE location score
• Previous scale for location effects (PIE score) wasn’t a true multivariate comparison of all locations at one time (because of limited data)
• PIE score was based on all symptomatic sequelae as an endpoint (including temporary and minimal symptoms)– The AVM Radiosurgery Study Group analysis of
complication outcome found that seizures and headaches were almost always temporary
![Page 40: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/40.jpg)
Patients: AVM SRS Complications• 85 patients with symptomatic neurological sequelae
following radiosurgery– 30 out of 332 Pittsburgh patients (9%)– +55 patients from other centers with no controls– 85 total with sequelae: 38 were permanent
• 337 control patients from Pittsburgh with no symptomatic sequelae and >2 yr follow-up– 519 duplicate controls were added to maintain a 9% rate
of symptomatic sequelae in the database
![Page 41: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/41.jpg)
Location: multivariate modelingVariable Regression coeff. SPIE score PIE score
Frontal 2.35 0.00 1
Temporal 3.48 1.89 2
Intraventricular 4.57 3.72 4
Parietal 5.24 4.83 2
Cerebellaral 5.26 4.87 2
Corpus Callosum 5.93 5.99 4
![Page 42: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/42.jpg)
Location: multivariate modelingVariable Regression coeff. SPIE score PIE score
Occipital 5.96 6.04 3
Medulla 6.51 6.96 4
Thalamus 6.96 7.71 4
Basal Ganglia 7.14 8.01 3
Pons/Midbrain 8.33 10.00 4
12-Gy-Volume 0.0747
![Page 43: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/43.jpg)
Then you can use the risk-location curves to predict the complication risk from the 12-Gy volume
You can use this curve before treatment to estimate 12 Gy volume from AVM diameter
0.5 1 2 5 10 20 50 1000.5
1
2
3
5
Volume (cc) receiving 12 Gy or more
Equi
vale
nt a
vera
ge d
iam
eter
(cm
)
![Page 44: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/44.jpg)
5 10 15 20 25 30 35 400
102030405060708090
100
Volume (cc) receiving 12 Gy or more
% AVM with Symptomatic Radiation Necrosis
pons/midbrain
thalamus
medulla
cerebellar
intaventricular
frontal
![Page 45: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/45.jpg)
5 10 15 20 25 30 35 400
102030405060708090
100
Volume (cc) receiving 12 Gy or more
% AVM with Symptomatic Radiation Necrosis
basal ganglia
corpus callosum
occipital
parietal
temporal
![Page 46: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/46.jpg)
SPIE score: multivariate modeling
Variable P value RegressionCoefficient
Risk ratio
(95% c.i.)
SPIE score <0.00001 0.7506+0.1243 2.12 (1.67-2.70)
12-Gy-Volume 0.00001 0.0734 +0.0191 1.08 (1.04-1.12)
Constant <0.00001 -7.8713 +0.8570
Marginal-12Gy-
volume
0.4691 Not in model Not significant
Maximum dose 0.5871 Not in model Not significant
![Page 47: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/47.jpg)
SPIE score: multivariate modeling
Variable P value Regression Coeff.
Prior hemorrhage 0.3879 Not significant
Treatment volume 0.6795 Not significant
Marginal dose (Dmin) 0.6150 Not significant
Number of isocenters 0.6614 Not significant
Max. /Min. Dose Ratio 0.8722 Not significant
PIE score 0.8780 Not significant
![Page 48: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/48.jpg)
AVM obliteration
![Page 49: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/49.jpg)
AVM obliteration
• Obliteration by angiography in 193/264 (73 %) • Obliteration by MR alone in 75/87 (86%) • 75% corrected obliteration rate (MR 96% accurate) • P(obliteration)=[1-P(miss)] x P(in-field obliteration)• Persistent out-of-field nidus in 29/281 (8.3%)
– Persistent out-of-field nidus in 18 % of embolized patients Vs. 6 % of non-embolized patients (p = 0.006).
![Page 50: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/50.jpg)
Persistent out-of-field nidus
Variable P(out-of-field nidus)
Prior embolization *0.0181
Spetzler grade 0.1741
Prior hemorrhage 0.2118
Nidus volume 0.2122
Stereotactic MR and angiography 0.5481
Prior Surgery 0.8628
![Page 51: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/51.jpg)
MutivariateAnalysis:In-field AVM
obliteration
Variable P(angiographic) P(mr or angiography)
Marginal dose *0.0093 *0.0029
Marginal dose squared *0.0190 *0.0072
Sex (male vs. female) *0.0025 *0.0273
Patient age 0.7698 0.3530
Cobalt-60 source age 0.9661 0.6558
Prior hemorrhage 0.2208 0.2170
Prior embolization 0.8350 0.8588
Treatment isodose 0.1582 0.0546
Spetzler AVM grade 0.6988 0.3067
Prior surgery 0.6394 0.1597
Treatment volume 0.4244 0.6967
MR plus angiography 0.9468 0.9488
![Page 52: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/52.jpg)
Probit linear-quadratic
8 10 12 14 16 18 20 22 24 26 280
20
40
60
80
100
0
20
40
60
80
100
Marginal Dose (Gy)
% with In-field Angiographic or MR Obliteration
/= -49.3 +5.3
47
39 103
18
116
27
19
![Page 53: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/53.jpg)
8 10 12 14 16 18 20 22 24 26 280
20
40
60
80
100
0
20
40
60
80
100
Marginal Dose (Gy)
% with In-field Angiographic or MR Obliteration
Male(n=165)
Female
34
41
18 50
18
53
63
7220
(n=186) p = 0.0273
![Page 54: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/54.jpg)
maximum obliteration rate model with / = 0
6 8 10 12 14 16 18 20 22 24 26 280
20
40
60
80
100
0
20
40
60
80
100
Marginal Dose (Gy)
% with Overall Angiographic or MR Obliteration
Not embolized(n=297)
Embolized(n=54)
51
30
94122
71.5 %maximum
87.9 %maximum
![Page 55: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/55.jpg)
Optimal dose for AVM obliteration• Maximum obliteration for dose-response curves
– logistic: 21.75 Gy LQ-Poisson: 24.75 Gy– MaxOblit model: 80,86,87,88 % at 20,23,25,30 Gy
• In-field obliteration Vs marginal dose:– 20-24 Gy: 126/135 (93.3 %)– 25 Gy: 85/100 (85 %) p = 0.049
• Overall obliteration Vs marginal dose:– 20-24 Gy: 113/135 (83.7 %)– 25 Gy: 81/100 (81 %) p = 0.589
![Page 56: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/56.jpg)
Recommendations: AVM dose-selection• Small AVM in low to medium risk locations should be treated
to marginal doses of 23 Gy– Higher doses may increase risk without higher obliteration
• Doses of 16-18 Gy seem prudent for risky locations– Lowering the dose only lowers complication risks slightly
• Marginal doses less than 15 Gy seem relatively ineffective• If possible, avoid embolization since targeting error increases
with embolization (from 6% to 18%)– Large AVMs may be better treated with volume-staged radiosurgery
treating half or one-third of the nidus every 6 months to marginal doses of 15-16 Gy
![Page 57: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/57.jpg)
![Page 58: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/58.jpg)
Dose Selection: vestibular schwannoma
Sweden before 1988: 18, 20 Gy and above1987-1990: 16-18 Gy1990-1993: 14-16 Gy1993-2000: 13-14 Gy2000-present: 12-13 Gy
Common margin dose at NYU = 12 GyEuropean centers = 11 Gy
![Page 59: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/59.jpg)
Dose-selection Acoustic tumors• Marginal doses of 12-13 Gy seem optimal from
the experience of many centers– Marginal doses of 13 Gy for all acoustics <3cm in
diameter, usually to the 50% isodose volume– 11, 11.5, 12 Gy for larger tumors or tumors where
hearing preservation is critical• The lowest dose for tumor control has not been defined
– Some intracanalicular tumors can be treated with higher isodoses and lower maximum dose
![Page 60: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/60.jpg)
![Page 61: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/61.jpg)
![Page 62: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/62.jpg)
Pituitary tumor GK dose-selection• Functional pituitary adenomas (usually small) give as
high a dose as possible without exceeding a maximum of 10 Gy to the optic chiasm or optic nerves, up to a maximum marginal tumor dose of 30 Gy
• Usual marginal doses are 16-25 Gy. Higher doses should give faster responses and greater chances of normalization
• Try custom beam blocking to reduce optic chiasm dose.
• Nonfunctional pituitary adenomas (usually larger) marginal doses of 12-14 Gy seem adequate
• Lower doses can be used for growth control (Vs hormone effects)• Dose depends on keeping optic chiasm/nerves < 8 Gy
![Page 63: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/63.jpg)
Parasagittal meningiomas
Meningiomas: no dose response for benign tumorsGrade 2/3: better response > 16 Gy
![Page 64: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/64.jpg)
Unbiopsied meningiomas• 219 pt.s with meningioma diagnosed by imaging• Marginal dose: 14 Gy median, range: 9-20 Gy• Actuarial local control 93.2 +2.7 % at 10 yrs
– No correlation with dose, volume or other factors in multivariate analysis
• Actuarial complication rate 8.8 +3.0 % • some correlation with volume & V12 Gy (p=0.06)
• Actuarial rate of misdiagnosis: 2.3 +1.4 %
![Page 65: Dose selection nyu 012815 2](https://reader035.fdocuments.us/reader035/viewer/2022062901/58f0f9e21a28ab7d138b4655/html5/thumbnails/65.jpg)
Meningioma radiosurgery dose-selection• Marginal doses of 12-15 Gy seem reasonable for
benign meningioma depending on size and location– Dose for parasellar/cavernous sinus tumors often depends
on keeping the optic chiasm/nerves to < 8-10 Gy – Try custom beam/sector blocking to reduce optic chiasm
dose. • Consider adding additional external beam radiotherapy
for atypical meningiomas to 50-55 Gy (particularly with prior surgery and uncertain dural margins) and all malignant meningiomas to 55-60 Gy